Amylyx Pharmaceuticals (AMLX) Price to Sales (2022 - 2024)

Amylyx Pharmaceuticals has reported Price to Sales for 3 years, with the latest figure at 407.89 in Q4 2024.

• On a quarterly basis, Price to Sales fell 4538.42% year-over-year to 407.89 in Q4 2024; TTM through Sep 2025 was 2345.48, a 209769.86% decrease from a year earlier, with the FY2024 full-year figure at 2.97, up 13.4% from the prior year.
• Price to Sales was 407.89 for Q4 2024 at Amylyx Pharmaceuticals, down from 533.86 in the prior quarter.
• The five-year high for Price to Sales was 4775.97 in Q3 2022, with the low at 407.89 in Q4 2024.
• Average Price to Sales over 3 years is 520.64, with a median of 21.18 recorded in 2023.
• The largest YoY upside for Price to Sales was 4335.54% in 2024 against a maximum downside of 4538.42% in 2024.
• Over 3 years, Price to Sales stood at 112.3 in 2022, then sank by 91.82% to 9.19 in 2023, then sank by 4538.42% to 407.89 in 2024.
• The last three Price to Sales figures came in at 407.89 (Q4 2024), 533.86 (Q3 2024), and 126.44 (Q2 2024), per Business Quant data.